December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Edgewise Therapeutics, Inc. - Common Stock (NQ:EWTX)

33.50 -0.51 (-1.50%)
Streaming Delayed Price Updated: 11:43 AM EDT, May 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Edgewise Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Edgewise Therapeutics Now Enrolling CANYON Phase 2 Clinical Trial of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD)
From Edgewise Therapeutics
Via Business Wire
News headline image
RBC Capital Says This Dystrophy Stock 'Is Worth A Look' ↗
 
Via Benzinga
News headline image
The Daily Biotech Pulse: Thumbs Down For Acadia's Pimavanserin, Pfizer Buys Stake In Valneva, AstraZeneca - Ionis Eplontersen Aces Rare Disease Trial ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Edgewise's Dystrophy Candidate Lowers Muscle Damage Biomarkers ↗
 
Via Benzinga
News headline image
Edgewise Therapeutics Announces Positive 2-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)
From Edgewise Therapeutics
Via Business Wire
News headline image
Recap: Edgewise Therapeutics Q1 Earnings ↗
Edgewise Therapeutics (NASDAQ:EWTX) reported its Q1 earnings results on Wednesday, May 11, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
New 2-Month Interim Data from the ARCH Open Label Study of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD) to be Presented at the Upcoming New Directions in Biology and Disease of Skeletal Muscle Conference
From Edgewise Therapeutics
Via Business Wire
News headline image
Edgewise Therapeutics to Present at Upcoming Investor Conferences
From Edgewise Therapeutics
Via Business Wire
News headline image
Analyst Ratings for Edgewise Therapeutics ↗
Over the past 3 months, 4 analysts have published their opinion on Edgewise Therapeutics (NASDAQ:EWTX) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
News headline image
Edgewise Therapeutics Reports First Quarter 2022 Financial Results
From Edgewise Therapeutics
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
On Friday, 166 companies set new 52-week lows. Points of Interest From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was... 
Via Benzinga
News headline image
Edgewise Therapeutics to Present at Upcoming Investor Conferences
From Edgewise Therapeutics
Via Business Wire
News headline image
Edgewise-Funded Natural History Trial of Becker Muscular Dystrophy (BMD) Now Enrolling
From Edgewise Therapeutics
Via Business Wire
News headline image
The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
On Thursday, 112 stocks made new 52-week lows. Noteworthy Highlights From Today's 52-Week Lows: Stanley Black & Decker (NYSE:SWK) was the largest firm by market... 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
On Wednesday, 63 companies set new 52-week lows. Noteworthy Mentions In Today's 52-Week Lows: The largest company by market cap to hit a new 52-week low was... 
Via Benzinga
News headline image
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
From Edgewise Therapeutics
Via Business Wire
News headline image
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings ↗
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments... 
Via Benzinga
News headline image
Edgewise Therapeutics to Participate at SVB Leerink 11th Annual Global Healthcare Conference on February 16
From Edgewise Therapeutics
Via Business Wire
News headline image
52 Biggest Movers From Friday ↗
Gainers Knightscope, Inc. (NASDAQ: KSCP) surged 175.6% to close at $3.40 on Friday. The company, on Thursday, priced its IPO at $10 per share. Imperial Petroleum Inc. (NASDAQ:... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Gainers Provention Bio (NASDAQ:PRVB) stoc... 
Via Benzinga
News headline image
Stocks Move Higher Midday, Still Pacing for Weekly Losses ↗
Stocks are continuing their rollercoaster pattern midday, as Wall Street attempts to lift itself out of the worst selloff since March 2020. 
Via Talk Markets
News headline image
33 Stocks Moving In Friday's Mid-Day Session ↗
Gainers Imperial Petroleum Inc. (NASDAQ: IMPP) shares jumped 126% to $2.6219. Imperial Petroleum, last month, posted Q3 revenue of $4.1 million. Yoshitsu Co., Ltd (NASDAQ: TKLF... 
Via Benzinga
News headline image
50 Biggest Movers From Yesterday ↗
Gainers Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) shares surged 63.7% to settle at $2.21 on Wednesday after the company announced that in preclinical studies its lead... 
Via Benzinga
News headline image
Mid-Afternoon Market Update: Nasdaq Down 300 Points; Annexon Shares Plunge ↗
Toward the end of trading Wednesday, the Dow traded up 0.24% to 36,711.36 while the NASDAQ fell 1.93% to 15,321.38. The S&P also fell, dropping 0.80% to 4,755.18. The U.S. has... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Gainers Lixte Biotech Holdings (NASDAQ:LIXT) stock increased by 70.4% to $2.3 during Wednesday's regular session. Trading volume for this security as of 12:31 EST is... 
Via Benzinga
News headline image
34 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares climbed 49.7% to $15.45 after the company announced it acquired exclusive rights to novel mRNA biomarkers. Data Storage... 
Via Benzinga
News headline image
Edgewise Therapeutics Shares Jump After Positive Data On Becker Muscular Dystrophy Study ↗
Edgewise Therapeutics Inc (NASDAQ: EWTX) posted positive topline results from Phase 1b trial of EDG-5506, designed to protect injury-susceptible fast skeletal... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Pfizer-BioNTech Partner For Shingles Vaccine, Annexon Huntington Disease Study Disappoints, Amneal Buys Neurology Assets ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Annexon Announces Mixed Phase 2 Data From Huntington Disease Trial Annexon,... 
Via Benzinga
News headline image
Edgewise Therapeutics Announces Positive Topline Results From the EDG-5506 Phase 1b Clinical Trial in Adults With Becker Muscular Dystrophy (BMD)
From Edgewise Therapeutics
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.